---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000047"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:38:10.697157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set

## Summary
- Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.
- Cash, equivalents and short-term investments total $139.4M as of Sept 30, 2024.
- Completed enrollment in Phase 2b IMPACT trial for MASH; top-line data expected Q2 2025.
- FDA agreed on Phase 3 obesity program design; IND submissions for up to three additional indications planned.
- Appointed Greg Weaver as CFO on November 11, 2024.

## SEC filing metadata
- accession: 0001326190-24-000047
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/0001326190-24-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/alt-20241112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000047
- JSON: https://secwatch.observer/filing/0001326190-24-000047.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.